Bioventus Inc. /zigman2/quotes/204270034/composite BVS +0.69% set terms Thursday of its initial public offering, in which the North Carolina-based joint pain and preservation company could raise up to $132.3 million and be valued at up to $976.2 million. The company is offering 7.35 million shares in the IPO, which is expected to price between $16 and $18 a share. The stock is expected to list on the Nasdaq under the ticker symbol "BVS." Bioventus expects there to be a total of 54.23 million Class A and Class B shares outstanding after the IPO. Morgan Stanley, J.P. Morgan, Goldman Sachs & Co. and Canaccord Genuity are listed as the underwriters. Bioventus is looking to go public at a time that the Renaissance IPO ETF /zigman2/quotes/207665280/composite IPO +1.22% has rallied 30.3% over the past three months while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.74% has gained 11.7%. The company had previously filed for an IPO in June 2016, but then requested a withdrawal in August 2016. At that time, the company said it would offer 8.82 million shares in the IPO, which was expected to be priced between $16 and $18, valuing the company at up to $599.4 million. The stock would have been listed on the Nasdaq under the ticker symbol "BIOV," and J.P. Morgan, Piper Jaffray, Stifel and Leerink Partners were listed as underwriters.